Patterns of immune checkpoint protein expression in MYC-overexpressing aggressive B-cell non-Hodgkin lymphomas View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2020-08-28

AUTHORS

Daniel J. Landsburg, Alexa Koike, Sunita D. Nasta, Jakub Svoboda, Stephen J. Schuster, Mariusz A. Wasik, Gabriel C. Caponetti

ABSTRACT

Given the poor prognosis of MYC-overexpressing diffuse large B cell lymphoma (DLBCL) and B cell lymphoma unclassifiable with features intermediate between DLBCL and Burkitt lymphoma/high grade B cell lymphoma (BCLU/HGBL), and preclinical data suggesting that MYC may regulate the antitumor immune response, we sought to characterize expression of immune checkpoint proteins on tumor tissue from patients diagnosed with these lymphomas. Immunohistochemical staining for immune checkpoint protein expression was applied to 56 cases of MYC-overexpressing DLBCL and BCLU/HGBL, 35 of which also harbored MYC rearrangement (MYC-R). Analysis revealed both frequent overexpression of immune checkpoint proteins as well as differences in overexpression patterns based upon MYC-R status, with MYC-R cases more likely to overexpress PD-L1 and PD-1 in the tumor microenvironment (50 vs. 15%, p = 0.02 and 32 vs. 5%, p = 0.02, respectively) but less likely to overexpress CTLA-4 and CD80 on tumor cells (34 vs. 71%, p = 0.01 and 34 vs. 81%, p = 0.001, respectively), as compared to cases without MYC-R. These data may suggest a biologic rationale for investigation of the effect of checkpoint inhibitor therapies in these subgroups of MYC-overexpressing DLBCL and BCLU/HGBL. More... »

PAGES

869-874

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00262-020-02708-3

DOI

http://dx.doi.org/10.1007/s00262-020-02708-3

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1130397345

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/32857184


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Biomarkers, Tumor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cyclophosphamide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Doxorubicin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Gene Expression Regulation, Neoplastic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Genes, myc", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immune Checkpoint Proteins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lymphoma, B-Cell", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Staging", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prednisone", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prognosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Recurrence", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Rituximab", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Vincristine", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University of Pennsylvania, Philadelphia, PA, USA", 
          "id": "http://www.grid.ac/institutes/grid.25879.31", 
          "name": [
            "University of Pennsylvania, Philadelphia, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Landsburg", 
        "givenName": "Daniel J.", 
        "id": "sg:person.01227167744.96", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01227167744.96"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Pennsylvania, Philadelphia, PA, USA", 
          "id": "http://www.grid.ac/institutes/grid.25879.31", 
          "name": [
            "University of Pennsylvania, Philadelphia, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Koike", 
        "givenName": "Alexa", 
        "id": "sg:person.016034737203.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016034737203.37"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Pennsylvania, Philadelphia, PA, USA", 
          "id": "http://www.grid.ac/institutes/grid.25879.31", 
          "name": [
            "University of Pennsylvania, Philadelphia, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nasta", 
        "givenName": "Sunita D.", 
        "id": "sg:person.01001105007.49", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01001105007.49"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Pennsylvania, Philadelphia, PA, USA", 
          "id": "http://www.grid.ac/institutes/grid.25879.31", 
          "name": [
            "University of Pennsylvania, Philadelphia, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Svoboda", 
        "givenName": "Jakub", 
        "id": "sg:person.0722677225.98", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0722677225.98"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Pennsylvania, Philadelphia, PA, USA", 
          "id": "http://www.grid.ac/institutes/grid.25879.31", 
          "name": [
            "University of Pennsylvania, Philadelphia, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schuster", 
        "givenName": "Stephen J.", 
        "id": "sg:person.011060364477.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011060364477.44"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Fox Chase Cancer Center and University of Pennsylvania, Philadelphia, USA", 
          "id": "http://www.grid.ac/institutes/grid.249335.a", 
          "name": [
            "Fox Chase Cancer Center and University of Pennsylvania, Philadelphia, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wasik", 
        "givenName": "Mariusz A.", 
        "id": "sg:person.01157554301.24", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01157554301.24"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Pennsylvania, Philadelphia, PA, USA", 
          "id": "http://www.grid.ac/institutes/grid.25879.31", 
          "name": [
            "University of Pennsylvania, Philadelphia, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Caponetti", 
        "givenName": "Gabriel C.", 
        "id": "sg:person.01103471633.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01103471633.20"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1186/s40880-017-0262-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1099676706", 
          "https://doi.org/10.1186/s40880-017-0262-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/leu.2017.103", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084128334", 
          "https://doi.org/10.1038/leu.2017.103"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s40425-019-0768-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1122119746", 
          "https://doi.org/10.1186/s40425-019-0768-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11899-016-0320-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028178341", 
          "https://doi.org/10.1007/s11899-016-0320-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/s41379-018-0193-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1111569928", 
          "https://doi.org/10.1038/s41379-018-0193-5"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2020-08-28", 
    "datePublishedReg": "2020-08-28", 
    "description": "Given the poor prognosis of MYC-overexpressing diffuse large B cell lymphoma (DLBCL) and B cell lymphoma unclassifiable with features intermediate between DLBCL and Burkitt lymphoma/high grade B cell lymphoma (BCLU/HGBL), and preclinical data suggesting that MYC may regulate the antitumor immune response, we sought to characterize expression of immune checkpoint proteins on tumor tissue from patients diagnosed with these lymphomas. Immunohistochemical staining for immune checkpoint protein expression was applied to 56 cases of MYC-overexpressing DLBCL and BCLU/HGBL, 35 of which also harbored MYC rearrangement (MYC-R). Analysis revealed both frequent overexpression of immune checkpoint proteins as well as differences in overexpression patterns based upon MYC-R status, with MYC-R cases more likely to overexpress PD-L1 and PD-1 in the tumor microenvironment (50 vs. 15%, p\u2009=\u20090.02 and 32 vs. 5%, p\u2009=\u20090.02, respectively) but less likely to overexpress CTLA-4 and CD80 on tumor cells (34 vs. 71%, p\u2009=\u20090.01 and 34 vs. 81%, p\u2009=\u20090.001, respectively), as compared to cases without MYC-R. These data may suggest a biologic rationale for investigation of the effect of checkpoint inhibitor therapies in these subgroups of MYC-overexpressing DLBCL and BCLU/HGBL.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00262-020-02708-3", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1096240", 
        "issn": [
          "0340-7004", 
          "1432-0851"
        ], 
        "name": "Cancer Immunology, Immunotherapy", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "70"
      }
    ], 
    "keywords": [
      "diffuse large B-cell lymphoma", 
      "B-cell lymphoma", 
      "immune checkpoint protein expression", 
      "immune checkpoint proteins", 
      "checkpoint protein expression", 
      "cell lymphoma", 
      "aggressive B-cell non-Hodgkin lymphoma", 
      "high-grade B-cell lymphoma", 
      "B-cell non-Hodgkin lymphoma", 
      "grade B-cell lymphoma", 
      "large B-cell lymphoma", 
      "checkpoint inhibitor therapy", 
      "protein expression", 
      "antitumor immune response", 
      "non-Hodgkin lymphoma", 
      "inhibitor therapy", 
      "PD-L1", 
      "PD-1", 
      "poor prognosis", 
      "preclinical data", 
      "CTLA-4", 
      "biologic rationale", 
      "immune response", 
      "immunohistochemical staining", 
      "MYC rearrangement", 
      "lymphoma", 
      "tumor tissue", 
      "frequent overexpression", 
      "tumor microenvironment", 
      "overexpression pattern", 
      "tumor cells", 
      "case of MYC", 
      "checkpoint proteins", 
      "HGBL", 
      "MYC", 
      "expression", 
      "CD80", 
      "prognosis", 
      "patients", 
      "therapy", 
      "cases", 
      "staining", 
      "subgroups", 
      "protein", 
      "tissue", 
      "microenvironment", 
      "overexpression", 
      "status", 
      "cells", 
      "response", 
      "rationale", 
      "patterns", 
      "data", 
      "differences", 
      "effect", 
      "investigation", 
      "analysis", 
      "features", 
      "rearrangement"
    ], 
    "name": "Patterns of immune checkpoint protein expression in MYC-overexpressing aggressive B-cell non-Hodgkin lymphomas", 
    "pagination": "869-874", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1130397345"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00262-020-02708-3"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "32857184"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00262-020-02708-3", 
      "https://app.dimensions.ai/details/publication/pub.1130397345"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-05-20T07:37", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220519/entities/gbq_results/article/article_847.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00262-020-02708-3"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00262-020-02708-3'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00262-020-02708-3'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00262-020-02708-3'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00262-020-02708-3'


 

This table displays all metadata directly associated to this object as RDF triples.

274 TRIPLES      22 PREDICATES      112 URIs      99 LITERALS      29 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00262-020-02708-3 schema:about N0be40abf13f44d8da088246ff48dfcf6
2 N11fcc1a6fd7b44698154375dc524f136
3 N2611930aa6cf48c8b6fadee7c4e0dd41
4 N484e782f34de4b9e918d364d9f9de641
5 N50368e56c931490ea3921061f735b865
6 N68ba94d177964be4936810a737345e20
7 N6b19c40d188c4ec7aa63a2b432de46e1
8 N716a6f5aa78747638f02c513ef42afa8
9 N7a26a3a546e74fe3ad45db5428dd3f28
10 N7c0eb96acdf944879285501d3ca49305
11 N8525440d481742febbb1fb57448b14b7
12 N88e0e207bb4f48ca99d43613438b9fff
13 N8945ca33823c495fa1ad4c0aaeaa904b
14 N8da1a7cb595b4b4994565e240027fd72
15 N96a78a53533d4e6f9c769e28323f7998
16 N97b9a74076ce44d885aa7b30073ea121
17 Na3d4e8f4bb014dad917cef3de694ef3d
18 Nb0af09d4369a4698a61bb81ac1535350
19 Nb1f2c57205e240c89feea270e9fe839d
20 Nb37cc3c26121455abc30e1b219011a85
21 Nba1fd6d746604feb979a6418224fd7c6
22 Nc42df43b85554d88b0fa14d6f7b236af
23 anzsrc-for:11
24 anzsrc-for:1112
25 schema:author N687f98eec28e445a8717a0ea3c883432
26 schema:citation sg:pub.10.1007/s11899-016-0320-7
27 sg:pub.10.1038/leu.2017.103
28 sg:pub.10.1038/s41379-018-0193-5
29 sg:pub.10.1186/s40425-019-0768-9
30 sg:pub.10.1186/s40880-017-0262-z
31 schema:datePublished 2020-08-28
32 schema:datePublishedReg 2020-08-28
33 schema:description Given the poor prognosis of MYC-overexpressing diffuse large B cell lymphoma (DLBCL) and B cell lymphoma unclassifiable with features intermediate between DLBCL and Burkitt lymphoma/high grade B cell lymphoma (BCLU/HGBL), and preclinical data suggesting that MYC may regulate the antitumor immune response, we sought to characterize expression of immune checkpoint proteins on tumor tissue from patients diagnosed with these lymphomas. Immunohistochemical staining for immune checkpoint protein expression was applied to 56 cases of MYC-overexpressing DLBCL and BCLU/HGBL, 35 of which also harbored MYC rearrangement (MYC-R). Analysis revealed both frequent overexpression of immune checkpoint proteins as well as differences in overexpression patterns based upon MYC-R status, with MYC-R cases more likely to overexpress PD-L1 and PD-1 in the tumor microenvironment (50 vs. 15%, p = 0.02 and 32 vs. 5%, p = 0.02, respectively) but less likely to overexpress CTLA-4 and CD80 on tumor cells (34 vs. 71%, p = 0.01 and 34 vs. 81%, p = 0.001, respectively), as compared to cases without MYC-R. These data may suggest a biologic rationale for investigation of the effect of checkpoint inhibitor therapies in these subgroups of MYC-overexpressing DLBCL and BCLU/HGBL.
34 schema:genre article
35 schema:inLanguage en
36 schema:isAccessibleForFree false
37 schema:isPartOf N564b5d98ba0e4607b74e72bac07a35b1
38 N912db8c3bf24498d90efa01af98cd887
39 sg:journal.1096240
40 schema:keywords B-cell lymphoma
41 B-cell non-Hodgkin lymphoma
42 CD80
43 CTLA-4
44 HGBL
45 MYC
46 MYC rearrangement
47 PD-1
48 PD-L1
49 aggressive B-cell non-Hodgkin lymphoma
50 analysis
51 antitumor immune response
52 biologic rationale
53 case of MYC
54 cases
55 cell lymphoma
56 cells
57 checkpoint inhibitor therapy
58 checkpoint protein expression
59 checkpoint proteins
60 data
61 differences
62 diffuse large B-cell lymphoma
63 effect
64 expression
65 features
66 frequent overexpression
67 grade B-cell lymphoma
68 high-grade B-cell lymphoma
69 immune checkpoint protein expression
70 immune checkpoint proteins
71 immune response
72 immunohistochemical staining
73 inhibitor therapy
74 investigation
75 large B-cell lymphoma
76 lymphoma
77 microenvironment
78 non-Hodgkin lymphoma
79 overexpression
80 overexpression pattern
81 patients
82 patterns
83 poor prognosis
84 preclinical data
85 prognosis
86 protein
87 protein expression
88 rationale
89 rearrangement
90 response
91 staining
92 status
93 subgroups
94 therapy
95 tissue
96 tumor cells
97 tumor microenvironment
98 tumor tissue
99 schema:name Patterns of immune checkpoint protein expression in MYC-overexpressing aggressive B-cell non-Hodgkin lymphomas
100 schema:pagination 869-874
101 schema:productId N2b1dd76080dc4a4ba358c95b985063d3
102 N5a7e0f08f4e64d019ecfd19bdf9bd5a4
103 Nd2726e6622e0494c92d8186e8ced6eff
104 schema:sameAs https://app.dimensions.ai/details/publication/pub.1130397345
105 https://doi.org/10.1007/s00262-020-02708-3
106 schema:sdDatePublished 2022-05-20T07:37
107 schema:sdLicense https://scigraph.springernature.com/explorer/license/
108 schema:sdPublisher Nc8d3e8bb0d28421390ac72a6a6cef0b1
109 schema:url https://doi.org/10.1007/s00262-020-02708-3
110 sgo:license sg:explorer/license/
111 sgo:sdDataset articles
112 rdf:type schema:ScholarlyArticle
113 N0be40abf13f44d8da088246ff48dfcf6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
114 schema:name Immune Checkpoint Proteins
115 rdf:type schema:DefinedTerm
116 N11fcc1a6fd7b44698154375dc524f136 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Survival Analysis
118 rdf:type schema:DefinedTerm
119 N1cc3ac0aa0f44aa6913378887f0ba9a2 rdf:first sg:person.011060364477.44
120 rdf:rest Ne6ec51bddf6d4d50b7d35fa688986bc8
121 N2611930aa6cf48c8b6fadee7c4e0dd41 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name Humans
123 rdf:type schema:DefinedTerm
124 N2b1dd76080dc4a4ba358c95b985063d3 schema:name doi
125 schema:value 10.1007/s00262-020-02708-3
126 rdf:type schema:PropertyValue
127 N484e782f34de4b9e918d364d9f9de641 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Biomarkers, Tumor
129 rdf:type schema:DefinedTerm
130 N50368e56c931490ea3921061f735b865 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Male
132 rdf:type schema:DefinedTerm
133 N55b5b45eb5f84455b2838ebeb28039a3 rdf:first sg:person.01103471633.20
134 rdf:rest rdf:nil
135 N564b5d98ba0e4607b74e72bac07a35b1 schema:volumeNumber 70
136 rdf:type schema:PublicationVolume
137 N5a7e0f08f4e64d019ecfd19bdf9bd5a4 schema:name pubmed_id
138 schema:value 32857184
139 rdf:type schema:PropertyValue
140 N687f98eec28e445a8717a0ea3c883432 rdf:first sg:person.01227167744.96
141 rdf:rest Nf81db85999604166b27f75716a81b00e
142 N68ba94d177964be4936810a737345e20 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Adult
144 rdf:type schema:DefinedTerm
145 N6b19c40d188c4ec7aa63a2b432de46e1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Prognosis
147 rdf:type schema:DefinedTerm
148 N716a6f5aa78747638f02c513ef42afa8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Prednisone
150 rdf:type schema:DefinedTerm
151 N7a26a3a546e74fe3ad45db5428dd3f28 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Lymphoma, B-Cell
153 rdf:type schema:DefinedTerm
154 N7ad882175d9f4a65b334101b235f592d rdf:first sg:person.01001105007.49
155 rdf:rest Ndc7d78e7034e483889176b57a4609553
156 N7c0eb96acdf944879285501d3ca49305 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Middle Aged
158 rdf:type schema:DefinedTerm
159 N8525440d481742febbb1fb57448b14b7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Recurrence
161 rdf:type schema:DefinedTerm
162 N88e0e207bb4f48ca99d43613438b9fff schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Vincristine
164 rdf:type schema:DefinedTerm
165 N8945ca33823c495fa1ad4c0aaeaa904b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Gene Expression Regulation, Neoplastic
167 rdf:type schema:DefinedTerm
168 N8da1a7cb595b4b4994565e240027fd72 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
169 schema:name Rituximab
170 rdf:type schema:DefinedTerm
171 N912db8c3bf24498d90efa01af98cd887 schema:issueNumber 3
172 rdf:type schema:PublicationIssue
173 N96a78a53533d4e6f9c769e28323f7998 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Antineoplastic Combined Chemotherapy Protocols
175 rdf:type schema:DefinedTerm
176 N97b9a74076ce44d885aa7b30073ea121 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Neoplasm Staging
178 rdf:type schema:DefinedTerm
179 Na3d4e8f4bb014dad917cef3de694ef3d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
180 schema:name Aged
181 rdf:type schema:DefinedTerm
182 Nb0af09d4369a4698a61bb81ac1535350 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
183 schema:name Female
184 rdf:type schema:DefinedTerm
185 Nb1f2c57205e240c89feea270e9fe839d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
186 schema:name Treatment Outcome
187 rdf:type schema:DefinedTerm
188 Nb37cc3c26121455abc30e1b219011a85 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
189 schema:name Doxorubicin
190 rdf:type schema:DefinedTerm
191 Nba1fd6d746604feb979a6418224fd7c6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
192 schema:name Genes, myc
193 rdf:type schema:DefinedTerm
194 Nc42df43b85554d88b0fa14d6f7b236af schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
195 schema:name Cyclophosphamide
196 rdf:type schema:DefinedTerm
197 Nc8d3e8bb0d28421390ac72a6a6cef0b1 schema:name Springer Nature - SN SciGraph project
198 rdf:type schema:Organization
199 Nd2726e6622e0494c92d8186e8ced6eff schema:name dimensions_id
200 schema:value pub.1130397345
201 rdf:type schema:PropertyValue
202 Ndc7d78e7034e483889176b57a4609553 rdf:first sg:person.0722677225.98
203 rdf:rest N1cc3ac0aa0f44aa6913378887f0ba9a2
204 Ne6ec51bddf6d4d50b7d35fa688986bc8 rdf:first sg:person.01157554301.24
205 rdf:rest N55b5b45eb5f84455b2838ebeb28039a3
206 Nf81db85999604166b27f75716a81b00e rdf:first sg:person.016034737203.37
207 rdf:rest N7ad882175d9f4a65b334101b235f592d
208 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
209 schema:name Medical and Health Sciences
210 rdf:type schema:DefinedTerm
211 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
212 schema:name Oncology and Carcinogenesis
213 rdf:type schema:DefinedTerm
214 sg:journal.1096240 schema:issn 0340-7004
215 1432-0851
216 schema:name Cancer Immunology, Immunotherapy
217 schema:publisher Springer Nature
218 rdf:type schema:Periodical
219 sg:person.01001105007.49 schema:affiliation grid-institutes:grid.25879.31
220 schema:familyName Nasta
221 schema:givenName Sunita D.
222 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01001105007.49
223 rdf:type schema:Person
224 sg:person.01103471633.20 schema:affiliation grid-institutes:grid.25879.31
225 schema:familyName Caponetti
226 schema:givenName Gabriel C.
227 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01103471633.20
228 rdf:type schema:Person
229 sg:person.011060364477.44 schema:affiliation grid-institutes:grid.25879.31
230 schema:familyName Schuster
231 schema:givenName Stephen J.
232 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011060364477.44
233 rdf:type schema:Person
234 sg:person.01157554301.24 schema:affiliation grid-institutes:grid.249335.a
235 schema:familyName Wasik
236 schema:givenName Mariusz A.
237 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01157554301.24
238 rdf:type schema:Person
239 sg:person.01227167744.96 schema:affiliation grid-institutes:grid.25879.31
240 schema:familyName Landsburg
241 schema:givenName Daniel J.
242 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01227167744.96
243 rdf:type schema:Person
244 sg:person.016034737203.37 schema:affiliation grid-institutes:grid.25879.31
245 schema:familyName Koike
246 schema:givenName Alexa
247 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016034737203.37
248 rdf:type schema:Person
249 sg:person.0722677225.98 schema:affiliation grid-institutes:grid.25879.31
250 schema:familyName Svoboda
251 schema:givenName Jakub
252 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0722677225.98
253 rdf:type schema:Person
254 sg:pub.10.1007/s11899-016-0320-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028178341
255 https://doi.org/10.1007/s11899-016-0320-7
256 rdf:type schema:CreativeWork
257 sg:pub.10.1038/leu.2017.103 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084128334
258 https://doi.org/10.1038/leu.2017.103
259 rdf:type schema:CreativeWork
260 sg:pub.10.1038/s41379-018-0193-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1111569928
261 https://doi.org/10.1038/s41379-018-0193-5
262 rdf:type schema:CreativeWork
263 sg:pub.10.1186/s40425-019-0768-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1122119746
264 https://doi.org/10.1186/s40425-019-0768-9
265 rdf:type schema:CreativeWork
266 sg:pub.10.1186/s40880-017-0262-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1099676706
267 https://doi.org/10.1186/s40880-017-0262-z
268 rdf:type schema:CreativeWork
269 grid-institutes:grid.249335.a schema:alternateName Fox Chase Cancer Center and University of Pennsylvania, Philadelphia, USA
270 schema:name Fox Chase Cancer Center and University of Pennsylvania, Philadelphia, USA
271 rdf:type schema:Organization
272 grid-institutes:grid.25879.31 schema:alternateName University of Pennsylvania, Philadelphia, PA, USA
273 schema:name University of Pennsylvania, Philadelphia, PA, USA
274 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...